Find Regadenoson Monohydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 313348-27-5, Lexiscan, Rapiscan, Cvt-3146, Regadenoson anhydrous, 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine
Molecular Formula
C15H18N8O5
Molecular Weight
390.35  g/mol
InChI Key
LZPZPHGJDAGEJZ-AKAIJSEGSA-N
FDA UNII
7AXV542LZ4

Regadenoson Monohydrate
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Regadenoson anhydrous is a Pharmacologic Cardiac Stress Test Agent. The mechanism of action of regadenoson anhydrous is as an Adenosine Receptor Agonist.
1 2D Structure

Regadenoson Monohydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide
2.1.2 InChI
InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1
2.1.3 InChI Key
LZPZPHGJDAGEJZ-AKAIJSEGSA-N
2.1.4 Canonical SMILES
CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)C4C(C(C(O4)CO)O)O)N
2.1.5 Isomeric SMILES
CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N
2.2 Other Identifiers
2.2.1 UNII
7AXV542LZ4
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cvt 3146

2. Cvt-3146

3. Cvt3146

4. Lexiscan

2.3.2 Depositor-Supplied Synonyms

1. 313348-27-5

2. Lexiscan

3. Rapiscan

4. Cvt-3146

5. Regadenoson Anhydrous

6. 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine

7. 7axv542lz4

8. Chembl317052

9. 1-(6-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide

10. Adenosine, 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]-

11. Regadenoson Monohydrate

12. Lexiscan (tn)

13. Cvt 3146

14. Regadenoson [usan:inn]

15. Unii-7axv542lz4

16. Adenosine, 2-(4-((methylamino)carbonyl)-1h-pyrazol-1-yl)-

17. Regadenoson [mi]

18. Regadenoson [inn]

19. Regadenoson (usan/inn)

20. Regadenoson; Cvt-3146

21. Dsstox_cid_31501

22. Dsstox_rid_97386

23. Regadenoson [mart.]

24. Dsstox_gsid_57712

25. Schembl678893

26. Gtpl5596

27. Dtxsid4057712

28. Chebi:135613

29. Hms3886o21

30. Amy27715

31. Ex-a2148

32. Hy-a0168

33. Tox21_113668

34. Bdbm50119132

35. S5358

36. Zinc13818943

37. Akos026750593

38. Ccg-268525

39. Cs-5612

40. Cv-3146

41. Db06213

42. 1-(6-amino-9-beta-d-ribofuranosyl-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide

43. Ncgc00249892-01

44. (1-(9-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl)pyrazol-4-yl)-n-methylcarboxamide

45. Ac-35838

46. As-56292

47. B5904

48. Cas-313348-27-5

49. Cvt-3146;cvt3146;cvt 3146

50. D05711

51. 348r275

52. J-018384

53. Q7307897

54. (1-{9-[(4s,2r,3r,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-n-methylcarboxamide

55. 1-[6-amino-9-((2r,3r,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-9h-purin-2-yl]-1h-pyrazole-4-carboxylic Acid Methylamide

56. 1-{6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purin-2-yl}-n-methyl-1h-pyrazole-4-carboxamide

57. 6-amino-2-[4-(methylcarbamoyl)-1h-pyrazol-1-yl]purine-9-yl-beta-d-ribofuranoside;1-(6-amino-9-((2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yloxy)-9h-purin-2-yl)-n-methyl-1h-pyrazole-4-carboxamide

2.4 Create Date
2005-08-09
3 Chemical and Physical Properties
Molecular Weight 390.35 g/mol
Molecular Formula C15H18N8O5
XLogP3-1.5
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count10
Rotatable Bond Count4
Exact Mass390.14001570 g/mol
Monoisotopic Mass390.14001570 g/mol
Topological Polar Surface Area187 Ų
Heavy Atom Count28
Formal Charge0
Complexity587
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameLexiscan
PubMed HealthRegadenoson (Injection)
Drug ClassesDiagnostic Agent, Cardiac Function
Drug LabelRegadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator [see Clinical Pharmacology (12.1)]. Regadenoson is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its structural formula...
Active IngredientRegadenoson
Dosage FormSolution
RouteIntravenous
Strength0.4mg/5ml (0.08mg/ml)
Market StatusPrescription
CompanyAstellas

2 of 2  
Drug NameLexiscan
PubMed HealthRegadenoson (Injection)
Drug ClassesDiagnostic Agent, Cardiac Function
Drug LabelRegadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator [see Clinical Pharmacology (12.1)]. Regadenoson is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its structural formula...
Active IngredientRegadenoson
Dosage FormSolution
RouteIntravenous
Strength0.4mg/5ml (0.08mg/ml)
Market StatusPrescription
CompanyAstellas

4.2 Drug Indication

Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)


FDA Label


This medicinal product is for diagnostic use only.

Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Regadenoson rapidly increases coronary blood flow (CBF) which is sustained for a short duration. Mean average peak velocity increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes. Myocardial uptake of the radiopharmaceutical is proportional to (CBF). Regadenoson increases blood flow in normal coronary arteries but not in stenotic (blocked) arteries. The significance of this finding is that stenotic arteries will take up less of the radiopharmaceutical than normal coronary arteries, resulting in a signal that is less intense in these areas.


5.2 MeSH Pharmacological Classification

Adenosine A2 Receptor Agonists

Compounds that selectively bind to and activate ADENOSINE A2 RECEPTORS. (See all compounds classified as Adenosine A2 Receptor Agonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
REGADENOSON ANHYDROUS
5.3.2 FDA UNII
7AXV542LZ4
5.3.3 Pharmacological Classes
Adenosine Receptor Agonists [MoA]; Pharmacologic Cardiac Stress Test Agent [EPC]; Adenosine Receptor Agonist [EPC]; Adenosine Receptor Agonists [MoA]
5.4 ATC Code

C01EB21


C01EB21

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


C - Cardiovascular system

C01 - Cardiac therapy

C01E - Other cardiac preparations

C01EB - Other cardiac preparations

C01EB21 - Regadenoson


5.5 Absorption, Distribution and Excretion

Absorption

The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. T max, injection = 1 to 3 minutes; Onset of pharmacodynamic response = 1 to 3 minutes; E max 12.3 ng/mL


Route of Elimination

58% of total regadenoson eliminate is via renal excretion


Volume of Distribution

Central compartment: 11.5 L; Steady state: 78.7 L


Clearance

Average plasma renal clearance = 450 mL/min. As this value is larger than the glomerular filtration rate, this suggests occurrence of renal tubular secretion.


5.6 Metabolism/Metabolites

The metabolism of regadenoson is unknown in humans. The cytochrome P450 enzyme system is not likely to be involved with the metabolism of regadenoson.


5.7 Biological Half-Life

Initial phase: 2-4 minutes; Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); Terminal phase: 2 hours


5.8 Mechanism of Action

Regadenoson is an selective low-affinity (Ki= 1.3 M) A2A receptor agonist that mimics the effects of adenosine in causing coronary vasodilatation and increasing myocardial blood flow. It is a very weak agonist of the A1 adenosine receptor (Ki > 16.5 M). Furthermore, it has negligible affinity to A2B and A3 adenosine receptors. Regadenoson is undergoing trials for use in pharmacological stress tests. Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731263400,"product":"REGADENOSON STABDARD(QTY:500 MG)","address":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL","city":"HYDERABAD, AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"DEMO S.APHARMACEUTICAL INDUSTRY","customerCountry":"GREECE","quantity":"0.00","actualQuantity":"0.5","unit":"GMS","unitRateFc":"75500","totalValueFC":"36801.2","currency":"USD","unitRateINR":6211169.8600000003,"date":"11-Nov-2024","totalValueINR":"3105584.93","totalValueInUsd":"36801.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"5508568","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.C-24, MSN HOUSE, INDUSTRIAL, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q1","strtotime":1611513000,"product":"REGADENOSON ANHYDROUS TEST LIC NO: TL\/AZ\/19\/001900 DT. 23.12.2019 (R&D) (10.05 GRAM \/ 4250\/GRAM USD)","address":"CLARIS CORPORATE HEAD QUARTERS, NR.PARIMAL RAILWAY CROSSING,","city":"ELLISBRIDGE,AHMEDABD,GUJARAT,INDIA","supplier":"ARCHIMICA","supplierCountry":"UNITED STATES","foreign_port":"NEW YORK - JOHN F. K","customer":"BAXTER HEALTHCARE CORPORATION","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"4271250","totalValueFC":"43129","currency":"USD","unitRateINR":"315431813","date":"25-Jan-2021","totalValueINR":"3154318.13","totalValueInUsd":"43129","indian_port":"AHMEDABAD AIR","hs_no":"29349990","bill_no":"2485192","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NEW YORK - JOHN F. K","supplierAddress":"","customerAddress":"CLARIS CORPORATE HEAD QUARTERS, NR.PARIMAL RAILWAY CROSSING,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674412200,"product":"REGADENOSON ANHYDROUS","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"CURIA","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"0.0981","unit":"KGS","unitRateFc":"4500000","totalValueFC":"444368.6","currency":"USD","unitRateINR":"370350000","date":"23-Jan-2023","totalValueINR":"36331335","totalValueInUsd":"444368.6","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"4323899","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685989800,"product":"REGADENOSON (QTY:80GMS, VALUE: USD 360000)","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N","city":"HYDERABAD","supplier":"CURIA","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.08","actualQuantity":"0.08","unit":"KGS","unitRateFc":"4500000","totalValueFC":"365272","currency":"USD","unitRateINR":"375299999.9","date":"06-Jun-2023","totalValueINR":"30023999.76","totalValueInUsd":"365272","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE, ROAD NO.3, BANJARA HILLS, Contact N"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1702837800,"product":"REGADENOSON (QTY:123GMS, VALUE: USD 553500)","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"CURIA","supplierCountry":"UNITED STATES","foreign_port":"CHICAGO O\\'HARE INT\\'L","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.12","actualQuantity":"0.123","unit":"KGS","unitRateFc":"4500000","totalValueFC":"560527.2","currency":"USD","unitRateINR":"379350000","date":"18-Dec-2023","totalValueINR":"46660050","totalValueInUsd":"560527.2","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"9288765","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"CHICAGO O\\'HARE INT\\'L","supplierAddress":"2460 W BENNETT STREET SPRINGFIELD,MISSOURI 65807 USA United States United States United States United States","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"}]
25-Jan-2021
11-Nov-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 313348-27-5 / Regadenoson Monohydrate API manufacturers, exporters & distributors?

Regadenoson Monohydrate manufacturers, exporters & distributors 1

10

PharmaCompass offers a list of Regadenoson Monohydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Regadenoson Monohydrate manufacturer or Regadenoson Monohydrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Regadenoson Monohydrate manufacturer or Regadenoson Monohydrate supplier.

PharmaCompass also assists you with knowing the Regadenoson Monohydrate API Price utilized in the formulation of products. Regadenoson Monohydrate API Price is not always fixed or binding as the Regadenoson Monohydrate Price is obtained through a variety of data sources. The Regadenoson Monohydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Regadenoson Monohydrate

Synonyms

313348-27-5, Lexiscan, Rapiscan, Cvt-3146, Regadenoson anhydrous, 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine

Cas Number

313348-27-5

Unique Ingredient Identifier (UNII)

7AXV542LZ4

About Regadenoson Monohydrate

Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

Regadenoson Monohydrate Manufacturers

A Regadenoson Monohydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Regadenoson Monohydrate, including repackagers and relabelers. The FDA regulates Regadenoson Monohydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Regadenoson Monohydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Regadenoson Monohydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Regadenoson Monohydrate Suppliers

A Regadenoson Monohydrate supplier is an individual or a company that provides Regadenoson Monohydrate active pharmaceutical ingredient (API) or Regadenoson Monohydrate finished formulations upon request. The Regadenoson Monohydrate suppliers may include Regadenoson Monohydrate API manufacturers, exporters, distributors and traders.

click here to find a list of Regadenoson Monohydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Regadenoson Monohydrate USDMF

A Regadenoson Monohydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Regadenoson Monohydrate active pharmaceutical ingredient (API) in detail. Different forms of Regadenoson Monohydrate DMFs exist exist since differing nations have different regulations, such as Regadenoson Monohydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Regadenoson Monohydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Regadenoson Monohydrate USDMF includes data on Regadenoson Monohydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Regadenoson Monohydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Regadenoson Monohydrate suppliers with USDMF on PharmaCompass.

Regadenoson Monohydrate WC

A Regadenoson Monohydrate written confirmation (Regadenoson Monohydrate WC) is an official document issued by a regulatory agency to a Regadenoson Monohydrate manufacturer, verifying that the manufacturing facility of a Regadenoson Monohydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Regadenoson Monohydrate APIs or Regadenoson Monohydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Regadenoson Monohydrate WC (written confirmation) as part of the regulatory process.

click here to find a list of Regadenoson Monohydrate suppliers with Written Confirmation (WC) on PharmaCompass.

Regadenoson Monohydrate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Regadenoson Monohydrate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Regadenoson Monohydrate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Regadenoson Monohydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Regadenoson Monohydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Regadenoson Monohydrate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Regadenoson Monohydrate suppliers with NDC on PharmaCompass.

Regadenoson Monohydrate GMP

Regadenoson Monohydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Regadenoson Monohydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Regadenoson Monohydrate GMP manufacturer or Regadenoson Monohydrate GMP API supplier for your needs.

Regadenoson Monohydrate CoA

A Regadenoson Monohydrate CoA (Certificate of Analysis) is a formal document that attests to Regadenoson Monohydrate's compliance with Regadenoson Monohydrate specifications and serves as a tool for batch-level quality control.

Regadenoson Monohydrate CoA mostly includes findings from lab analyses of a specific batch. For each Regadenoson Monohydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Regadenoson Monohydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Regadenoson Monohydrate EP), Regadenoson Monohydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Regadenoson Monohydrate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty